High Court Seeks US Take On Sandoz-Amgen Biosimilar Battle

Law360, New York (June 20, 2016, 1:35 PM EDT) -- The U.S. Supreme Court on Monday asked the U.S. solicitor general whether it should review a Federal Circuit ruling on the obligations of biosimilar makers, signaling that the justices are interested in stepping into a major battle between Sandoz and Amgen.

The invitation followed a conference on Thursday at which the justices for the first time met to discuss a pair of petitions that Sandoz and Amgen recently submitted. As is customary, the invitation was succinct, saying only that “the solicitor general is invited to file...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.